| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | FORM S-3 |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Third quarter 2026 net product revenue of $21 million; cash and cash equivalents of $189.2 million as of September 30, 2026 |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
ZYNLONTA data to be featured across 5 oral presentations and multiple posters |
| 03 Nov 2026 | FORM S-4 |
| 29 Oct 2026 | SCHEDULE 13G |
| 13 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 7, 2026, by and between ADC Therapeutics SA, a société anonyme domiciled in Epalinges, Canton of Vaud, Switzerland, and organized under the laws of Switzerland ... |
| 14 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 | FORM S-8 |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 |
| 27 Jul 2026 | SCHEDULE 13G |
| 02 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 30, 2026, the Board of Directors of ADC Therapeutics SA (the “Company”), with the advice of its independent compensation consultant, approved one-time retention awards (“Awards”) to certain of the Company’s employees, including i... |
| 02 Jul 2026 |
Form 4: Zaki Mohamed, Chief Medical Officer
Received 213,900 shares as a grant or award |
| 02 Jul 2026 |
Form 4: Graham Peter J, Chief Legal Officer
Received 221,100 shares as a grant or award |
| 02 Jul 2026 |
Form 4: Carmona Jose, Chief Financial Officer
Received 203,700 shares as a grant or award |
| 02 Jul 2026 |
Form 4: Mallik Ameet, Director
Received 675,000 shares as a grant or award |
| 24 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Planned 17% workforce reduction expected to generate annualized estimated savings of approximately $10m, enhancing financial flexibility |
| 03 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing con... |
Loading...